Drug Price Differentials Caused by Formularies and Price Caps
This paper analyses the behaviour of drug firms facing the threat of having their drugs excluded from the formulary of health care providers. The paper obtains two main results. One is that drug firms offer discounts to health care providers to avoid going off-list when competing in a free-entry monopolistically competitive setting, and that discounts obtained by health care providers do not cause prices to rise outside managed care. The second result is that price caps affect how prices evolve over time. Drug firms set higher introductory prices, but raise these less dramatically over time, when health care providers find it increasingly difficult to off-list older drugs.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 10 (2003)
Issue (Month): 1 ()
|Contact details of provider:|| Web page: http://www.tandfonline.com/CIJB20|
|Order Information:||Web: http://www.tandfonline.com/pricing/journal/CIJB20|
When requesting a correction, please mention this item's handle: RePEc:taf:ijecbs:v:10:y:2003:i:1:p:35-48. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty)
If references are entirely missing, you can add them using this form.